Imatinib Mesylate Tablet, Film Coated
Product Images NDC 59651-241

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 59651-241). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Progression Free Survival (itt Principle) (Imatinib Fig1)

The text describes a figure (Figure 1) showing the Progression-Free Survival of patients with Imatinib Mesylate arm and IFN+Ara-C arm. The number of patients with progression, censored at discontinuation, and censored at last follow-up are also shown. The Hazard Ratio and Log-rank Test statistic are also provided. The x-axis shows the number of months since randomization.*

FDA Label Image

Figure 2: Time To Progression To Ap Or Bc (itt Principle) (Imatinib Fig2)

This is a figure that shows the time taken for patients to progress to AP or BC using the ITT principle. The data is presented in a graph with the number of patients who progressed and were censored at discontinuation or last follow-up, respectively. The hazard ratio and p-value are also provided. The graph shows that the Imatinib Mesylate arm had a lower risk of progression compared to the IFN+Ara-C arm. The x-axis represents the time in months since randomization, while the y-axis represents the percentage of patients.*

FDA Label Image

Package Label-principal Display Panel (100 mg)

FDA Label Image

Package Label-principal Display Panel (400 mg)

FDA Label Image

Package Label-principal Display Panel (400 mg (Blister Carton Label))

The text describes Figure 5 which shows the overall survival for a study 2 with ITT population. The X-axis shows the time in months and the Y-axis shows the percentage of survival. The data shows the number of patients observed under censorship and the one that has been assigned the treatment. The data also provides the hazard ratio of 0.45 and p-value of 0.0187.*

FDA Label Image

Imatinib Fig6

Imatinib Mesylate Tablets by Aurobindo Pharma USA, Inc. is a prescription medicine containing 90 film-coated tablets. Each tablet contains Imatinib mesylate equivalent to 100mg of imatinib free base. It is used as per the instructions given in the package insert. It should be stored between 20°C to 25°C and protect it from moisture. It should be dispensed in a light container, USP. The package is distributed by Aurobindo Pharma USA, Inc. and made in India.*

FDA Label Image

Imatinib Fig7

FDA Label Image

Imatinib Fig8

This is a package of Imatinib Mesylate Tablets, with each tablet containing 400 mg of the active ingredient. The package contains 30 unit-dose tablets and should be stored at room temperature between 20-25°C. The tablets are distributed by Aurobindo Pharma USA, Inc. in East Windsor, NJ and are made in India. The package is only available with a prescription, and it is important to keep it out of the reach of children.*

FDA Label Image

Chemical Structure (Imatinib Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.